Parkman Healthcare Partners LLC Buys New Position in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Parkman Healthcare Partners LLC acquired 200,500 shares of Zimmer Biomet Holdings, valued at approximately $22.7 million, making it the fund's 11th largest holding.
• Zimmer Biomet's most recent quarterly earnings showed a 7% revenue increase year-over-year, reporting earnings per share of $2.07, exceeding analysts' expectations.
• The company announced a quarterly dividend of $0.24, which will be paid on October 31st, reflecting a 0.9% dividend yield.

Parkman Healthcare Partners LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 200,500 shares of the medical equipment provider's stock, valued at approximately $22,693,000. Zimmer Biomet makes up about 2.7% of Parkman Healthcare Partners LLC's portfolio, making the stock its 11th largest holding. Parkman Healthcare Partners LLC owned approximately 0.10% of Zimmer Biomet at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ZBH. Brighton Jones LLC purchased a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $204,000. Bridgefront Capital LLC purchased a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $218,000. Deutsche Bank AG raised its holdings in shares of Zimmer Biomet by 0.3% in the 4th quarter. Deutsche Bank AG now owns 922,403 shares of the medical equipment provider's stock valued at $97,433,000 after acquiring an additional 3,170 shares in the last quarter. Ensign Peak Advisors Inc raised its holdings in shares of Zimmer Biomet by 7.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 58,523 shares of the medical equipment provider's stock valued at $6,182,000 after acquiring an additional 4,000 shares in the last quarter. Finally, Focus Partners Wealth raised its holdings in shares of Zimmer Biomet by 16.2% in the 4th quarter. Focus Partners Wealth now owns 16,528 shares of the medical equipment provider's stock valued at $1,760,000 after acquiring an additional 2,303 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Down 0.8%

ZBH traded down $0.87 on Tuesday, hitting $103.84. 1,282,597 shares of the company were exchanged, compared to its average volume of 1,220,309. The firm has a fifty day simple moving average of $98.89 and a two-hundred day simple moving average of $99.61. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $114.72. The stock has a market capitalization of $20.57 billion, a PE ratio of 25.27, a price-to-earnings-growth ratio of 2.06 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same period last year, the company earned $2.01 EPS. Zimmer Biomet's revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet's dividend payout ratio is currently 23.36%.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZBH. Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Evercore ISI decreased their price objective on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. Royal Bank Of Canada raised their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Canaccord Genuity Group decreased their price objective on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Finally, UBS Group raised their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a report on Friday, August 8th. Nine research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $111.00.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider owned 20,424 shares in the company, valued at $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.70% of the stock is currently owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.